Key Drivers
- Gross Margin
- Cash Burn
- Leverage Risk
AIAI Summary
RARE should now be viewed less as a “pipeline optionality” name and more as a high-stakes commercialization-and-financing execution test, where investors need proof that revenue can stabilize, margins can expand, and cash burn can narrow fast enough to make the 2027 profitability target credible before leverage and litigation pressure mount further.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Leverage Risk
RARE has strong gross margins and near-term liquidity, but persistent operating losses, heavy cash burn, and rising leverage make the stock fundamentally weak despite a higher sales multiple.
Price Behavior
Key Price Behavior Insights:
- •New High
- •Momentum Fade
- •Mid-$24 Support
RARE remains mildly constructive after a rally to a new last month high, but the sharp pullback from $26.84 to $25.00 shows fading momentum and puts focus on holding the mid-$24s while reclaiming the mid-$26s to confirm the breakout.
Sharp drop from $26.84 to $25.00 after the recent high
Sentiment & News
Key News Insights:
- •Revenue Miss
- •Crysvita Weakness
- •Investor Outreach
Ultragenyx missed Q1 estimates with a wider loss and softer Crysvita sales, partly offset by growth in Evkeeza and Dojolvi, while investor outreach and rare-disease advocacy remained active.
The quarter likely pressures near-term sentiment on RARE, but product diversification and ongoing investor engagement may help limit downside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings